Proton pump inhibitors (PPIs) are a group of medicines that decrease stomach acid production. They can help relieve symptoms of chronic acid reflux (GERD) and stomach ulcers. Proton pump inhibitors primarily treat conditions that arise when stomach acid irritates or damages parts of the digestive system, like stomach, duodenum (the part of your small intestine closest to the stomach) or food tube (esophagus).

The global Oral Proton Pump Inhibitors (PPIs) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Oral Proton Pump Inhibitors (PPIs) Industry Forecast” looks at past sales and reviews total world Oral Proton Pump Inhibitors (PPIs) sales in 2023, providing a comprehensive analysis by region and market sector of projected Oral Proton Pump Inhibitors (PPIs) sales for 2024 through 2030.

With Oral Proton Pump Inhibitors (PPIs) sales broken down by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Proton Pump Inhibitors (PPIs) industry.

This Insight Report provides a comprehensive analysis of the global Oral Proton Pump Inhibitors (PPIs) landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest development
• M&A activity

This report also analyzes the strategies of leading global companies with a focus on Oral Proton Pump Inhibitors (PPIs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Proton Pump Inhibitors (PPIs) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Proton Pump Inhibitors (PPIs) and breaks down the forecast by:

• Type
• Application
• Geography
• Market size

United States market for Oral Proton Pump Inhibitors (PPIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oral Proton Pump Inhibitors (PPIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oral Proton Pump Inhibitors (PPIs) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oral Proton Pump Inhibitors (PPIs) players cover:

• Takeda Pharmaceutical
• Pfizer
• AstraZeneca
• Eisai Co.
• Cipla Ltd.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Proton Pump Inhibitors (PPIs) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

1. Rabeprazole
2. Ilaprazole
3. Esomeprazole
4. Omeprazole
5. Pantoprazole
6. Others

Segmentation by Application:

1. Hospital Pharmacy
2. Retail Pharmacy

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration:

• Takeda Pharmaceutical
• Pfizer
• AstraZeneca
• Eisai Co.
• Cipla Ltd.
• Aurobindo Pharma
• Teva
• Hetero Drugs
• Nang Kuang Pharmaceutical
• Jean Marie Pharmacal
• Lizhu Group
• Luoxin Pharmaceutical
• Jiangsu Haosen Pharmaceutical Group
• Chengdu Dikang Pharmaceutical
• Jumpcan Pharmaceutical

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global Oral Proton Pump Inhibitors (PPIs) market?
2. What factors are driving Oral Proton Pump Inhibitors (PPIs) market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Oral Proton Pump Inhibitors (PPIs) market opportunities vary by end market size?
5. How does Oral Proton Pump Inhibitors (PPIs) break out by Type, by Application?